home All News open_in_new Full Article

Eupraxia Pharmaceuticals Reports Third Quarter 2025 Financial Results

Durable symptom and tissue responses observed out to 52 weeks following a single treatment with EP-104GI Enrollment continues in Phase 2b portion of the RESOLVE Trial, with topline data expected by Q3 2026 Completed $80.5 million public offering supported by leading life science investors Cash runway to fund pipeline development and operations into the first […]


today 1 week ago attach_file Culture

attach_file Culture
attach_file Culture
attach_file Culture
attach_file Culture
attach_file Culture
attach_file Culture
attach_file Economics
attach_file Culture
attach_file Culture
attach_file Culture
attach_file Culture
attach_file Economics
attach_file Culture
attach_file Culture
attach_file Culture
attach_file Culture
attach_file Economics
attach_file Culture
attach_file Culture
attach_file Society


ID: 1703364513
Add Watch Country

arrow_drop_down